RIM
SCLN

Ranger Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Ranger Investment Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-143,280
Closed -$1.58M – 150
2017
Q2 		$1.58M Hold
143,280
– – 0.11% 70
2017
Q1 		$1.4M Buy
143,280
+27,590
+24% +$276K 0.1% 71
2016
Q4 		$1.25M Buy
115,690
+7,500
+7% +$75K 0.09% 93
2016
Q3 		$1.11M Buy
108,190
+8,290
+8% +$90.3K 0.08% 99
2016
Q2 		$1.3M Sell
99,900
-26,580
-21% -$348K 0.08% 84
2016
Q1 		$1.39M Buy
126,480
+4,100
+3% +$36.5K 0.09% 86
2015
Q4 		$1.13M Sell
122,380
-8,460
-6% -$70.8K 0.07% 88
2015
Q3 		$908K Buy
130,840
+9,950
+8% +$85.2K 0.05% 94
2015
Q2 		$1.19M Buy
120,890
+1,350
+1% +$12.3K 0.06% 97
2015
Q1 		$1.06M Buy
119,540
+23,050
+24% +$184K 0.05% 93
2014
Q4 		$845K Sell
96,490
-1,390
-1% -$11.3K 0.04% 92
2014
Q3 		$674K Buy
+97,880
New +$587K 0.04% 93

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ranger Investment Management's SCLN Position: Q3 2017 in Review

Ranger Investment Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 143,280 shares — an estimated $1.58M sold.

Ranger Investment Management first reported a position in SCLN in Q3 2014 and held it in 12 quarters. The position peaked at $1.58M in Q2 2017. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Ranger Investment Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Ranger Investment Management sold 143,280 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $1.58M.
  • Ranger Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2014 and held it in 12 quarters.
  • Ranger Investment Management's Sciclone Pharmaceuticals Inc position peaked at $1.58M in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Ranger Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.